Maximizing Responses to Anti-PD1 Immunotherapy With PSMA-targeted Alpha Therapy in mCRPC
Status:
Recruiting
Trial end date:
2028-06-01
Target enrollment:
Participant gender:
Summary
This is a phase I/II study investigating the combination of 225Ac-J591 (a drug that can
deliver radiation to prostate cancer cells) with pembrolizumab (immunotherapy, a drug that
increases the immune system's ability to destroy cancer cells). This study will assess
whether 225Ac-J591 + pembrolizumab + androgen receptor pathway inhibitor (ARPI) is more
effective against prostate cancer than pembrolizumab + ARPI alone.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Weill Medical College of Cornell University
Collaborators:
Merck Sharp & Dohme Corp. United States Department of Defense